Aquestive Therapeutics (AQST) risk factors
Item 1A of every Aquestive Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors65 risks10 new10 dropped11 reworded
New geopolitical risks highlight potential supply chain disruptions from baseline tariffs on imports from China, Canada, and Mexico. The company added operational and regulatory risks concerning its deployment of artificial intelligence across R&D and manufacturing. Intellectual property and clinical trial progression risks remain central to regulatory approvals for product candidates like Anaphylm.
Filed Mar 04, 2026 - FY2024 10-K risk factors65 risks
Company faces substantial accumulated deficits totaling $363.2 million and relies heavily on a single customer and licensed products like Sympazan, Suboxone, and Azstarys. Operations depend on complex manufacturing processes with limited suppliers for thin film foil and API. Capital needs require ongoing financing and debt management, including $45.0 million in 13.5% Notes.
Filed Mar 05, 2025